Close
Found 0 results for your search. Showing 0 to 0.
No results could be found for your search.
x Close Search
Close

Publications

The epidemiology of meningococcal disease in India.
Sinclair, D; Preziosi, M-P; Jacob John, T; GREENWOOD, B;
2010
Tropical medicine & international health, (2010).15 12 10.1111/j.1365-3156.2010.02660.x.
An update to "The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe".
JIT, M; Mangen, M-JJ; Melliez, H; Yazdanpanah, Y; Bilcke, J; Salo, H; EDMUNDS, WJ; Beutels, P;
2010
Vaccine, (2010).28 47 10.1016/j.vaccine.2010.08.060.
Comparative Critical Review of Cost-Effectiveness Tools of Pneumococcal Conjugate Vaccine (Pcv).
Chaiyakunapruk, N; Somkrua, R; Hutubessy, R; Restrepo, AM H; Melegaro, A; EDMUNDS, J; Beutels, P;
2010
Value in health, (2010).13 7
ISOLATION OF VIABLE PLASMODIUM FALCIPARUM MEROZOITES TO DEFINE ERYTHROCYTE INVASION EVENTS AND ADVANCE VACCINE AND DRUG DEVELOPMENT.
Boyle, MJ; Wilson, DW; Richards, JS; Riglar, DT; Tetteh, KK; CONWAY, DJ; Ralph, SA; Baum, J; Beeson, JG;
2010
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, (2010).83 5
Critical interactions between Global Fund-supported programmes and health systems: a case study in Lao People's Democratic Republic.
MOUNIER-JACK, S; RUDGE, JW; Phetsouvanh, R; Chanthapadith, C; COKER, R;
2010
Health policy and planning, (2010).25 Sup Suppl. 10.1093/heapol/czq056.
Design of a Phase IIb, randomized, controlled, double-blind, multi-centre study to evaluate the efficacy, safety, and immunogenicity of the GMZ2 candidate malaria vaccine in Ugandan, Ghanaian, Burkinabe and Gabonese children aged 12-60 months.
Noor, RA; Thiesen, M; Mordmuller, B; MILLIGAN, P; Atuguba, F; Sirima, S; Issifou, S; BOJANG, K; Kironde, F; Tiono, A; Okech, B; Chilengi, R; Ngoa, A; Mukasa, K; Jepsen, S;
2010
Malaria journal, (2010).9 Suppl 2 10.1186/1475-2875-9-s2-p26.
Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster.
Russell, FM; Carapetis, JR; Satzke, C; Tikoduadua, L; Waqatakirewa, L; Chandra, R; Seduadua, A; Oftadeh, S; Cheung, YB; Gilbert, GL; MULHOLLAND, EK;
2010
Clinical and vaccine immunology, (2010).17 12 10.1128/CVI.00117-10.
Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines.
White, MT; Griffin, JT; RILEY, EM; DRAKELEY, CJ; Moorman, AM; Sumba, PO; Kazura, JW; Ghani, AC; John, CC;
2010
Proceedings Biological sciences / The Royal Society, (2010).278 1710 10.1098/rspb.2010.1697.
Supporting new vaccine introduction decisions: lessons learned from the Hib Initiative experience.
Hajjeh, RA; Privor-Dumm, L; EDMOND, K; O'Loughlin, R; Shetty, S; GRIFFITHS, UK; Bear, AP; COHEN, AL; Chandran, A; Schuchat, A; MULHOLLAND, EK; Santosham, M;
2010
Vaccine, (2010).28 43 10.1016/j.vaccine.2010.07.028.
Global use of Haemophilus influenzae type b conjugate vaccine.
Ojo, LR; O'Loughlin, RE; COHEN, AL; Loo, JD; EDMOND, KM; Shetty, SS; Bear, AP; Privor-Dumm, L; GRIFFITHS, UK; Hajjeh, R;
2010
Vaccine, (2010).28 43 10.1016/j.vaccine.2010.07.074.